- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01876264
Crohn's Extent of Resection Trial (CERT)
Crohn's Extent of Resection Trial (CERT): A Randomised Controlled Trial Comparing Anastomotic Disease Recurrence Following 2cm Versus 10cm Resection Margins for Patients With Ileocolic Crohn's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be conducted as a randomised controlled trial. The patient will be blinded to the procedure undertaken, as will the endoscopist performing the 6 month post operative colonoscopy. It is not possible to blind the operating team, for obvious reasons.
Patients undergoing elective or urgent ileocolic resection, both primary and redo resections, will be invited to participate in the trial. Randomisation will take place in the operating theatre after a conventional ileocolic resection has been performed. Those patients randomised to the modest resection (10cm margin) will have an additional 8cm of distal small bowel resected prior to the formation of the surgical anastomosis.
All patients will be seen in the colorectal clinic at approximately 6 weeks post operatively for their routine follow up appointment, as is current practice. A colonoscopy will be performed at 6 months post operatively to assess the anastomosis, in keeping with our current practice. Any additional follow up will be at the discretion of the colorectal or gastroenterological teams, in keeping with their clinical practice.
Patients recruited to the trial will not have any additional ongoing following up directly related to their trial participation. At 5 years following the recruitment of the a patient, the medical notes will be reviewed to identify those patients who have had symptomatic recurrence, further surgery and to assess the duration of medication-free interval following surgery.
Performing a colonoscopy at 6 months post operatively to assess the appearances of the surgical anastomosis will assess the primary endpoint. This will be performed by a senior gastroenterological trainee or consultant gastroenterologist who is familiar with assessment of post operative Crohn's disease and the Rutgeert's score. The appearances of the anastomosis will be scored, and biopsies taken from around the anastomosis to assess for microscopic changes. The use of the Rutgeert's score is widely accepted by the gastroenterological community as the standard assessment tool for post operative anastomotic disease recurrence in patients with Crohn's disease.
The duration of medication-free interval following resection will be assessed from review of the medical notes. This is clinically relevant to patients, as it has been previously shown that quality of life is improved in patients who do not have to take regular medication.
The duration of symptom-free interval will be assessed from review of the medical notes. This is clinically relevant to patients, as abdominal symptoms such as pain and bloating have a significantly deleterious effect on quality of life.
The duration of time to reoperation for Crohn's disease recurrence at the surgical anastomosis will be assessed from the clinical notes. This is of relevance to the patient population as well as the medical community. Crohn's disease commonly recurs, necessitating further surgery. Multiple operations resulting in resection of the bowel results in a reduction in the length of bowel available for absorption of nutrients from food. Ultimately, patients may develop short bowel syndrome. This requires total parenteral nutrition, with the associated risks this carries, and may require small bowel transplantation.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Oxford, United Kingdom, OX3 7LJ
- Oxford University Hospitals NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 16 years or above.
- Patients with ileocolic Crohn's disease requiring surgical resection
Exclusion Criteria:
- Patients unable to give informed consent
- Patients requiring formation of a stoma at the time of surgical resection
- Patients having less than 200cm of small bowel as assessed intra-operatively
- Simultaneous strictureplasty or small bowel resection
- Age <16 or >80
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Extended resection
Patients undergoing an extended resection are subjected to a traditional ileocolic resection with a 2cm macroscopically normal proximal margin.
A further 8cm of ileum is then resected from the proximal margin prior to formation of the ileocolic anastomosis
|
|
|
Active Comparator: Conventional resection
Patients undergoing a traditional ileocolic resection for Crohn's disease with a 2cm proximal macroscopically disease-free margin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endoscopic recurrence
Time Frame: 6 months post operatively
|
The primary objective of the study is to assess whether undertaking a modest ileocolic resection (10cm margins) leads to a reduction in the incidence of Crohn's disease recurrence at the surgical anastomosis as assessed by colonoscopy 6 months post operatively, when compared to a conventional ileocolic resection (2cm margin).
|
6 months post operatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Medication-free interval
Time Frame: 5 years post operatively
|
To assess the impact of undertaking a modest ileocolic resection (10cm margin) on the duration of medication-free interval following surgery, with respect to disease-modifying drugs (e.g.
azathioprine), when compared to a conventional ileocolic resection (2cm margin)
|
5 years post operatively
|
|
Symptom-free interval
Time Frame: 5 years post operatively
|
To assess the impact of undertaking a modest ileocolic resection (10cm margin) on the duration of the symptom-free interval following surgery, when compared to a conventional ileocolic resection (2cm margin)
|
5 years post operatively
|
|
Time to reoperation
Time Frame: 5 years post operatively
|
To assess the impact of undertaking a modest ileocolic resection (10cm margin) on the interval to reoperation (if clinically needed) for anastomotic recurrence when compared to a conventional ileocolic resection (2cm margin)
|
5 years post operatively
|
|
Extent of plexitis
Time Frame: 1 month postoperatively
|
To assess the extent of plexitis through the length of macroscopically normal small bowel that is resected
|
1 month postoperatively
|
Collaborators and Investigators
Investigators
- Principal Investigator: Richard E Lovegrove, MBBS MD FRCS, Worcestershire Acute Hospitals NHS Trust
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CERT2013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrence
-
Portuguese Oncology Institute, CoimbraCompletedColorectal Cancer | Recurrence, Local NeoplasmPortugal
-
Paracelsus Medical UniversityHeinrich-Heine University, Duesseldorf; Poznan University of Medical Sciences; University Hospital of Ferrara and other collaboratorsCompletedToxicity | Local Neoplasm RecurrenceAustria
-
Chinese PLA General HospitalRecruitingHCC | Recurrence TumorChina
-
Saint Petersburg State University, RussiaInstitute of Cytology of the Russian Academy of Sciences; The Russian Science...Active, not recruitingCancer | Anesthesia | Cancer RecurrenceRussian Federation
-
Aarhus University HospitalRecruitingFear of Cancer RecurrenceDenmark
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityCompletedLocal Recurrence of Malignant Tumor of Rectum | Local Re-Recurrence of Malignant Tumor of Rectum
-
General Hospital GroeningeUniversitaire Ziekenhuizen KU Leuven; Jessa Hospital; University Hospital, Ghent and other collaboratorsEnrolling by invitation
-
The University of Hong KongHealth and Medical Research FundRecruitingCancer | Fear of Cancer RecurrenceHong Kong
-
German Centre for Assessment and Evaluation of...Not yet recruitingComplication | Continence | Potency | Biochemical RecurrenceGermany
-
Dallas VA Medical CenterTerminatedSolid Tumors | Cancer RecurrenceUnited States
Clinical Trials on Extended resection
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Montreal General HospitalJewish General HospitalRecruitingRecurrence | Crohn Disease | Crohn's IleocolitisCanada
-
Odense University HospitalRecruitingCrohn's Disease of Terminal IleumDenmark
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityPeking Union Medical College Hospital; Shanghai Changzheng HospitalRecruiting
-
Case Comprehensive Cancer CenterNot yet recruitingGlioblastoma | Brain TumorUnited States
-
Qilu Hospital of Shandong UniversityRecruitingthe Incidence of Complications Related to Rectal Anastomosis After Neoadjuvant TherapyChina
-
AHEPA University HospitalCompletedMortality | Patient Outcome Assessment | Morbidity
-
Moscow Clinical Scientific CenterRecruitingCecal Neoplasms | Colonic Neoplasms MalignantRussian Federation
-
RenJi HospitalRecruiting
-
Fudan UniversityUnknown